

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104
 Estimated average burden
 hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>BAKER G LEONARD JR</u> <hr/> (Last) (First) (Middle) <u>C/O CORCEPT THERAPEUTICS</u> <u>INCORPORATED</u> <u>275 MIDDLEFIELD ROAD</u> <hr/> (Street) <u>MENLO</u> <u>CA</u> <u>94025</u> <u>PARK</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>04/14/2004</u>	3. Issuer Name and Ticker or Trading Symbol <u>CORCEPT THERAPEUTICS INC [CORT]</u> <hr/> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
No securities	0	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Stock	(1)	(8)	Common Stock	8,019	(3)	I	Sutter Hill Entrepreneurs Fund (AI), LP ⁽⁴⁾
Series B Preferred Stock	(1)	(8)	Common Stock	5,775	(3)	I	Sutter Hill Entrepreneurs Fund (AI), LP ⁽⁴⁾
Series BB Preferred Stock	(1)	(8)	Common Stock	1,228	(2)	I	Sutter Hill Entrepreneurs Fund (AI), LP ⁽⁴⁾
Series C Preferred Stock	(1)	(8)	Common Stock	7,400	(2)	I	Sutter Hill Entrepreneurs Fund (AI), LP ⁽⁴⁾
Series A Preferred Stock	(1)	(8)	Common Stock	20,304	(3)	I	Sutter Hill Entrepreneurs Fund (QP), LP ⁽⁵⁾
Series B Preferred Stock	(1)	(8)	Common Stock	14,619	(3)	I	Sutter Hill Entrepreneurs Fund (QP), LP ⁽⁵⁾
Series BB Preferred Stock	(1)	(8)	Common Stock	3,109	(2)	I	Sutter Hill Entrepreneurs Fund (QP), LP ⁽⁵⁾
Series C Preferred Stock	(1)	(8)	Common Stock	18,736	(2)	I	Sutter Hill Entrepreneurs Fund (QP), LP ⁽⁵⁾
Series A Preferred Stock	(1)	(8)	Common Stock	791,586	(3)	I	Sutter Hill Ventures, a California Limited Partnership ⁽⁶⁾

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B Preferred Stock	(1)	(8)	Common Stock	569,940	(3)	I	Sutter Hill Ventures, a California Limited Partnership ⁽⁶⁾
Series BB Preferred Stock	(1)	(8)	Common Stock	121,780	(2)	I	Sutter Hill Ventures, a California Limited Partnership ⁽⁶⁾
Series C Preferred Stock	(1)	(8)	Common Stock	732,882	(2)	I	Sutter Hill Ventures, a California Limited Partnership ⁽⁶⁾
Series A Preferred Stock	(1)	(8)	Common Stock	207	(3)	D	
Series BB Preferred Stock	(1)	(8)	Common Stock	3,369	(2)	D	
Series C Preferred Stock	(1)	(8)	Common Stock	201,863	(2)	D	
Series A Preferred Stock	(1)	(8)	Common Stock	6,279	(3)	I	By trust ⁽⁹⁾
Series B Preferred Stock	(1)	(8)	Common Stock	4,521	(3)	I	By trust ⁽⁹⁾
Series BB Preferred Stock	(1)	(8)	Common Stock	966	(2)	I	By trust ⁽⁹⁾
Series C Preferred Stock	(1)	(8)	Common Stock	5,812	(2)	I	By trust ⁽⁹⁾
Series A Preferred Stock	(1)	(8)	Common Stock	110,544	(3)	I	By limited partnership ⁽⁷⁾
Series B Preferred Stock	(1)	(8)	Common Stock	77,322	(3)	I	By limited partnership ⁽⁷⁾
Series BB Preferred Stock	(1)	(8)	Common Stock	12,392	(2)	I	By limited partnership ⁽⁷⁾
Series C Preferred Stock	(1)	(8)	Common Stock	56,516	(2)	I	By limited partnership ⁽⁷⁾

Explanation of Responses:

- Immediately
- Each share is convertible without consideration into one (1) share of Common Stock.
- Each share is convertible without consideration into three (3) shares of Common Stock.
- The reporting person is a managing director of the general partner of Sutter Hill Entrepreneurs Fund (AI), LP and shares voting and investment power with seven other managing directors of the general partner of the entity that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.
- The reporting person is a managing director of the general partner of Sutter Hill Entrepreneurs Fund (QP), LP and shares voting and investment power with seven other managing directors of the general partner of the entity that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.
- The reporting person is a managing director of the general partner of Sutter Hill Ventures, A California Limited Partnership and shares voting and investment power with six other managing directors of the general partner of the entity that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.
- The reporting person is a general partner of the limited partnership. The reporting person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.
- Not applicable
- The reporting person is a trustee of the trust. The reporting person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

/s/ Fred Kurland, CFO of
Corcept Therapeutics 04/14/2004
Incorporated attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY FOR SECTION 16 REPORTING

The undersigned hereby appoints Joseph K. Belanoff, in his capacity as Chief Executive Officer of Corcept Therapeutics Incorporated (the "Company"), Andrew Galligan, in his capacity as Chief Financial Officer of the Company, and either of them with full power of substitution or their respective successors in any such offices, as the attorney-in-fact of the undersigned to execute and file with the Securities and Exchange Commission ("SEC") and any other authority required by the rules and regulations of the SEC or any market or exchange on which shares of the Company are traded and to submit to the Company, in the place and stead of the undersigned, SEC Forms 3, 4 and 5 and any successor reporting forms required by the SEC in connection with purchases and sales of securities of the Company and any other transactions in securities of the Company reportable on any such form. This Power of Attorney shall be effective

until revoked by a written instrument executed by the undersigned and delivered to the Company at its headquarters to the attention of the Chief Financial Officer.

Dated: February 12, 2002

/s/ G. Leonard Baker, Jr.

Name: G. Leonard Baker, Jr.